Are countries using global fund support to implement HIV drug resistance surveillance? A review of funded HIV grants.
Clin Infect Dis
; 54 Suppl 4: S250-3, 2012 May.
Article
en En
| MEDLINE
| ID: mdl-22544183
ABSTRACT
The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) is the largest funder of human immunodeficiency virus (HIV) prevention and treatment programs worldwide. Since 2002, the Global Fund has encouraged grant recipients to implement drug resistance surveillance (DRS) as part of treatment programs. We reviewed documentation of 147 grants funded in 2004-2008 (funding rounds 4-8) to assess grantees' use of funds to support HIV DRS. Overall, 94 grants (64%) described HIV DRS as part of the national treatment program. However, only 32 grants (22%) specifically documented DRS as a grant-funded activity. This review provides baseline information suggesting limited use by countries of Global Fund financing to support HIV DRS. Additional assessment is required to evaluate barriers to using Global Fund grants to support DRS.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Salud Global
/
Organización de la Financiación
Tipo de estudio:
Screening_studies
Límite:
Humans
Idioma:
En
Año:
2012
Tipo del documento:
Article